SynthesisPhysiological reports2021
Effects of acetazolamide on control of breathing in sleep apnea patients: Mechanistic insights using meta-analyses and physiological model simulations.
Synthesis in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Effects of acetazolamide on control of breathing in sleep apnea patients: Mechanistic insights using meta-analyses and physiological model simulations.Physiological reports · 2021Pooled it
- Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial.Thorax · 2026Trial
- Combination Drug Therapy with Acetazolamide, Eszopiclone ± Venlafaxine for Obstructive Sleep Apnea (RESCUE-Combo): A Randomized, Double-Blind, Placebo-controlled Clinical Trial.Annals of the American Thoracic Society · 2025Trial
- Quantification of ventilatory control in sleep apnea: from physiological insight to computable loop gain.Sleep · 2026Review
- Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Unraveling sleep apnea dynamics: quantifying loop gain using dynamical modeling of ventilatory control.Sleep · 2026Article
- A perspective on precision medicine in obstructive sleep apnea: from pathophysiological phenotyping to integrated management pathways.Frontiers in medicine · 2026Article
- Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea.Cardiac failure review · 2026Review
- Drug therapy for obstructive sleep apnoea: promises and challenges.Lancet (London, England) · 2025Article
- Insights, recommendations, and research priorities for central sleep apnea: report from an expert panel.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Morphological Prediction of Continuous Positive Airway Pressure-associated Acute Respiratory Instability.Annals of the American Thoracic Society · 2025Article
- Article
- Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2024Review
- Effects of acetazolamide on sleep disordered breathing in pulmonary vascular disease: a randomised controlled trial.ERJ open research · 2024Article
- Acetazolamide as an Add-on Therapy Following Barbed Reposition Pharyngoplasty in Obstructive Sleep Apnea: A Randomized Controlled Trial.Life (Basel, Switzerland) · 2024Article
- Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance.Expert opinion on pharmacotherapy · 2024Review
- The Present and Future of the Clinical Use of Physiological Traits for the Treatment of Patients with OSA: A Narrative Review.Journal of clinical medicine · 2024Review
- Loop Gain as a Predictor of Blood Pressure Response in Patients Treated for Obstructive Sleep Apnea: Secondary Analysis of a Clinical Trial.Annals of the American Thoracic Society · 2024Article
- Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome.Signal transduction and targeted therapy · 2023Review
- Premedication with acetazolamide: Is its use for postoperative pain and stress control after laparoscopic ovariectomy in dogs ruled out?Veterinary medicine and science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Obstructive and central sleep apnea affects ~1 billion people globally and may lead to serious cardiovascular and neurocognitive consequences, but treatment options are limited. High loop gain (ventilatory instability) is a major pathophysiological mechanism underlying both types of sleep apnea and can be lowered pharmacologically with acetazolamide, thereby improving sleep apnea severity. However, individual responses vary and are strongly correlated with the loop gain reduction achieved by acetazolamide. To aid with patient selection for long-term trials and clinical care, our goal was to understand better the factors that determine the change in loop gain following acetazolamide in human subjects with sleep apnea. Thus, we (i) performed several meta-analyses to clarify how acetazolamide affects ventilatory control and loop gain (including its primary components controller/plant gain), and based on these results, we (ii) performed physiological model simulations to assess how different baseline conditions affect the change in loop gain. Our results suggest that (i) acetazolamide primarily causes a left shift of the chemosensitivity line thus lowering plant gain without substantially affecting controller gain; and (ii) higher controller gain, higher paCO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.